What Estradiol Is Actually Doing While Your Labs Look Normal

The benefits nobody can feel, and why waiting for a symptom means waiting too long.

A thirty-one-year-old man walked into a research lab in 1997.

He was six foot eight, because his growth plates never closed. His bone density was low, at thirty-one. When they scanned his heart, the calcium score in his arteries came back at 48. The published average for a man in his thirties is 5.

So you would assume a cholesterol problem. His total cholesterol was 130, better than almost everyone reading this.

He was born without a working estrogen receptor. He makes estradiol. He has plenty of it. He has nothing to read it with.

By thirty-one his arteries were hardening and his bones were thinning, and not one of those things was something he could feel happening.

That is what this post is about.

The benefits you cannot feel

Nobody notices their arteries staying flexible. Nobody feels their bones holding their mineral. Nobody wakes up aware that their brain burned fuel normally overnight.

Which means when those things stop, you do not notice that either, and by the time a symptom finally shows up the process behind it has usually been running for years. That is the flaw in how menopause has been handled for four decades. Hot flashes announce themselves, so hot flashes got treated. Everything else was quiet, so everything else got ignored. Here is what the measurements show while a woman still feels fine and her labs still read normal.

Her brain changes before any test says so

In 2021 a team imaged the brains of women across the menopause transition, and the result is worth sitting with. Women in the middle of it did fine on memory testing, the same scores as women who had not started. If you were her doctor and ran those tests, you would write "normal," and you would be correct.

Then you look at the scans taken from the same women on the same day. Gray matter has already shifted. So has white matter, the wiring between regions, and the rate at which the brain burns glucose for fuel. Some of it begins in perimenopause, while she is still having periods. The brain is not helpless here, and after menopause some of what shifted comes back. But the sequence is the part that matters: the inside moves first and the tests notice later.

A randomized study ran it in the other direction. Women who had been on hormone therapy for about a decade were assigned either to keep taking it or to stop, then scanned two years later. The ones who kept it held their brain metabolism. The ones who stopped lost it. And in the small region that goes quiet earliest in Alzheimer's disease, the women who stayed on conjugated equine estrogen, the horse-derived version, declined there anyway. They kept taking a hormone and lost the region regardless. What separated them was which molecule was in the bottle, though which molecule a woman had been on was not itself the randomized part, so that piece is an observation inside the trial rather than the trial's own verdict.

That study is small, and it measures brain fuel use rather than who eventually gets a diagnosis. What it shows is estradiol holding a measurement that otherwise falls.

Her bones are losing about two percent a year

After menopause, bone density at the spine falls by roughly two percent a year, and at the hip by about half that. Ten years of that is a fifth of her spine. It does not ache or show in the mirror. Very often the first time the system tells her anything is when something breaks.

You cannot run a forty-year randomized trial of a person's estradiol level, but genetics already ran one. Some people inherit variants that set a slightly higher lifetime estradiol, some slightly lower, and which one you got was settled at conception rather than by how carefully you live. That matters, because the standard objection to hormone research is that the women taking hormones were simply healthier to begin with. Your genotype did not choose you for being health conscious.

Across more than 175,000 men, a drop in lifetime estradiol of about 10 pg/mL, small enough to look like noise on a lab slip, tracked with clearly more broken bones. Wrist fractures more than doubled. The same analysis run on testosterone, in the same people at the same time, found no causal effect on fracture risk at all. The hormone doing the heavy lifting in the skeleton is the one everybody files under women's health. Two things about that study are worth knowing as you read it. It was done in men, and the biology of estradiol at the bone-building cell is not sex specific. And it answers what the deficiency does, not what replacing it fixes.

And when a woman asks what to do about her bones, she is very often handed vitamin D. I believe in vitamin D and take it every day. It is not a substitute for the hormone that is leaving.

Her skin runs on a clock that is not her birthday

You have seen the line: "you lose thirty percent of your collagen in the first five years after menopause." It is on half the clinic websites in America. I went looking for the source, and it traces back to a 1983 paper that does not contain the number. A figure came loose from its origin and traveled on its own.

What the research actually found is more interesting. Untreated postmenopausal women lost about 45 percent of their skin collagen across the first fifteen years after menopause. Women on hormone replacement did not lose it. And skin collagen showed no relationship at all to how old the woman was. It did not track her age. It tracked how long she had been without the hormone.

That is the same clock as the bone and the brain, turning up in a thigh biopsy taken in 1987 by researchers who were not trying to prove anything about menopause. One note on that study: the treated women received estradiol and testosterone together, so it cannot hand the whole effect to one molecule.

Her arteries, on the same clock

Estradiol acts on the lining of the blood vessel directly. It switches on an enzyme that makes nitric oxide, the muscle in the artery wall relaxes, and the artery opens, within about five minutes. That is far too fast to be the hormone entering the nucleus and changing which genes get read. It is the man in the opening paragraphs in reverse: he had the hormone and nothing to receive it with, and his arteries paid for it by thirty-one.

Cholesterol is part of this and nowhere near all of it. As one of the clearest reviews of the vascular biology put it, "Estrogen-induced alterations in serum lipids account for only approximately one third of the observed clinical benefits of estrogen." The rest is the hormone working on the vessel itself.

Then the clock again. The trial that tested timing on purpose found that in women who started estradiol within six years of menopause, thickening of the carotid artery wall slowed to roughly half the rate. In women who started ten or more years out, nothing. That same trial looked at the coronary arteries and did not find it there, so the claim is exactly what was measured: started early, estradiol slows the wall the trial could see. Not how old she is. How long she has been without it.

The one thing systemic estradiol does not fix

Oral estradiol does not treat vaginal dryness, painful sex or recurrent urinary tract infections, and that is not my opinion. It has been randomized. Pooling eight trials and 4,700 women, vaginal estrogen cut recurrent urinary infections by more than half. Oral estrogen did nothing measurable.

The reason is a small, elegant chain. Estrogen at that tissue feeds glycogen, glycogen feeds lactobacillus, lactobacillus makes lactic acid, and lactic acid holds the pH low. E. coli does not want to live at a low pH. After menopause the chain unwinds, the pH climbs, and the neighborhood gets colonized from the gut. You are not really treating an infection. You are restoring a pH.

So a woman on a perfectly managed dose with an ideal blood level can still have thin, irritated tissue. That is not a failure of her hormone. It is a delivery problem with a known answer: local treatment, applied to the tissue that needs it, alongside whatever she takes systemically.

While most providers use vaginal estradiol for this, a much more effective and beneficial approach is testosterone cream applied to the vaginal tissue, which provides all of the benefits of an estradiol cream and more.

A word about the pill and the patch

They are the same drug. The pill and the patch are both 17-beta estradiol, the identical molecule. What differs is the route, and the route decides how your body handles it. A pill goes through the liver before it reaches the rest of you. A patch goes through skin and skips the liver entirely. The liver is not a hallway, it is an organ that responds, and in nine women measured both ways, the pill lowered LDL cholesterol and raised HDL while the patch did neither. Triglycerides went up on the pill, which sounds like a catch until you read the next column of the same table: the particle that actually builds plaque went down, and the extra triglyceride was cleared out of the blood rather than turned into LDL.

Oral estradiol is my first choice and I will argue for it in any room. The patch is a genuine second option, not a booby prize. If a woman understands all of this and still does not want to take a pill, I will write her a patch without spending the appointment arguing about it.

The clot question is the one that frightens people, and the observational data there do lean toward the patch. I gave that evidence its own article, with the honest number attached and every limitation on it: The Post That Refutes Itself. What has never existed is a randomized trial showing that oral estradiol alone causes clots.

Why does nearly every clinician say patch? Not because of a trial. Nobody ran a study and discovered the pill was dangerous. A generation of doctors watched what the 2002 headlines did to their colleagues and quietly chose the option nobody gets sued for. That is a liability posture, not a safety finding, and it costs women benefits they were never told they had.

I have written the long version of that argument separately: What the Estrogen Patch Shortage Reveals About the Spectacular Failure of Modern Menopause Medicine.

One thing that is not optional

A woman who still has her uterus does not take estradiol on its own. Unopposed estradiol thickens the uterine lining, and that is the one risk in this entire post that is neither subtle nor slow. She needs progesterone alongside it, and my preference is oral micronized progesterone, the molecule the body actually makes, rather than a synthetic progestin. That belongs in a conversation with your own clinician, not in a decision made off an article.

The sentence does not reverse, though, and this is where it usually gets reversed. Losing the uterus does not end the reason to take progesterone. Protecting the lining is one of the jobs progesterone does, not the whole list, and the receptors behind the sleep, the calm, the bone and the breast tissue were never in the uterus to begin with. They are all still there after a hysterectomy. What a woman without a uterus does not need is a synthetic progestin, which was built for that single job. That is a completely different sentence from not needing progesterone, and the two get swapped constantly. To learn more about those benefits, read this one: What Progesterone Actually Does at Every Age.

What this all adds up to

A molecule running things you cannot feel running. Her brain, while her testing reads normal. Her bones, at about two percent a year. Her skin, on a clock that has nothing to do with her birthday. Her arteries, on that same clock.

None of it hurts. That is the entire point.

If you are deciding something real, do it with a clinician who will read the papers with you.

⚠️ Educational content, not individual medical advice, diagnosis or a treatment recommendation. Nothing here tells any woman what to take, and nobody should start, stop or change a prescription because of an article. Doses named above are study facts, not instructions. Your own labs and history belong in a one on one.

🩺 DNP led telehealth hormone optimization. Book a consultation and find everything: withinyou.health/links

Sources

Arnal J-F, Fontaine C, Billon-Galés A, et al. Estrogen receptors and endothelium. Arterioscler Thromb Vasc Biol. 2010;30:1506-1512.

Brincat M, Moniz CF, Studd JWW, Darby AJ, Magos A, Cooper D. Sex hormones and skin collagen content in postmenopausal women. Br Med J (Clin Res Ed). 1983;287(6402):1337-1338.

Brincat M, Moniz CF, Kabalan S, et al. Decline in skin collagen content and metacarpal index after the menopause and its prevention with sex hormone replacement. Br J Obstet Gynaecol. 1987;94(2):126-129.

Brincat MP. Hormone replacement therapy and the skin. Maturitas. 2000;35(2):107-117.

Chen YY, Su TH, Lau HH. Estrogen for the prevention of recurrent urinary tract infections in postmenopausal women: a meta-analysis of randomized controlled trials. Int Urogynecol J. 2021;32(1):17-25.

Chow RWY, Handelsman DJ, Ng MKC. Minireview: rapid actions of sex steroids in the endothelium. Endocrinology. 2010;151(6):2411-2422.

Davis SR, Robinson PJ, Jane F, White S, White M, Bell RJ. Intravaginal testosterone improves sexual satisfaction and vaginal symptoms associated with aromatase inhibitors. J Clin Endocrinol Metab. 2018;103(11):4146-4154.

Finkelstein JS, Brockwell SE, Mehta V, et al. Bone mineral density changes during the menopause transition in a multiethnic cohort of women. J Clin Endocrinol Metab. 2008;93(3):861-868.

Hodis HN, Mack WJ, Henderson VW, et al. Vascular effects of early versus late postmenopausal treatment with estradiol. N Engl J Med. 2016;374(13):1221-1231.

Mendelsohn ME, Karas RH. The protective effects of estrogen on the cardiovascular system. N Engl J Med. 1999;340(23):1801-1811.

Mosconi L, Berti V, Dyke J, et al. Menopause impacts human brain structure, connectivity, energy metabolism, and amyloid-beta deposition. Sci Rep. 2021;11(1):10867.

Nethander M, Vandenput L, Eriksson AL, Windahl S, Funck-Brentano T, Ohlsson C. Evidence of a causal effect of estradiol on fracture risk in men. J Clin Endocrinol Metab. 2019;104(2):433-442.

Raine-Fenning NJ, Brincat MP, Muscat-Baron Y. Skin aging and menopause: implications for treatment. Am J Clin Dermatol. 2003;4(6):371-378.

Rasgon NL, Geist CL, Kenna HA, Wroolie TE, Williams KE, Silverman DHS. Prospective randomized trial to assess effects of continuing hormone therapy on cerebral function in postmenopausal women at risk for dementia. PLoS ONE. 2014;9(3):e89095.

Raz R, Stamm WE. A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med. 1993;329(11):753-756.

Sehl ME, Ganz PA. Potential mechanisms of age acceleration caused by estrogen deprivation: do endocrine therapies carry the same risks? JNCI Cancer Spectr. 2018;2(3):pky035.

Sudhir K, Chou TM, Chatterjee K, et al. Premature coronary artery disease associated with a disruptive mutation in the estrogen receptor gene in a man. Circulation. 1997;96(10):3774-3777.

Sudhir K, Chou TM, Messina LM, et al. Endothelial dysfunction in a man with disruptive mutation in oestrogen-receptor gene. Lancet. 1997;349:1146-1147.

Walsh BW, Schiff I, Rosner B, Greenberg L, Ravnikar V, Sacks FM. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med. 1991;325(17):1196-1204.